Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2013 4
2014 4
2015 4
2016 5
2017 8
2018 5
2019 6
2020 4
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, Ulmann G, Blanchet B, Batista R, Goldwasser F, Thomas Schoemann A. Tardy C, et al. Among authors: thomas schoemann a. Cancer Chemother Pharmacol. 2024 Feb;93(2):169-175. doi: 10.1007/s00280-023-04574-z. Epub 2023 Aug 24. Cancer Chemother Pharmacol. 2024. PMID: 37620675
Predictive factors associated with pemetrexed acute toxicity.
Bonnet M, Jouinot A, Boudou-Rouquette P, Seif V, Villeminey C, Arrondeau J, Vidal M, Batista R, Wislez M, Blanchet B, Goldwasser F, Thomas-Schoemann A. Bonnet M, et al. Among authors: thomas schoemann a. Eur J Clin Pharmacol. 2023 May;79(5):635-641. doi: 10.1007/s00228-023-03478-4. Epub 2023 Mar 23. Eur J Clin Pharmacol. 2023. PMID: 36951965
Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
Monribot A, Huillard O, Khoudour N, Préta LH, Blanchet B, Cabanes L, Batista R, Pallet N, Chouchana L, Goldwasser F, Sogni P, Thomas-Schoemann A. Monribot A, et al. Among authors: thomas schoemann a. Br J Clin Pharmacol. 2023 Apr;89(4):1486-1490. doi: 10.1111/bcp.15674. Epub 2023 Feb 8. Br J Clin Pharmacol. 2023. PMID: 36709977 Free article.
Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients.
Minot-This MS, Boudou-Rouquette P, Jouinot A, de Percin S, Balakirouchenane D, Khoudour N, Tlemsani C, Chauvin J, Thomas-Schoemann A, Goldwasser F, Blanchet B, Alexandre J. Minot-This MS, et al. Among authors: thomas schoemann a. Pharmaceutics. 2022 Jun 9;14(6):1224. doi: 10.3390/pharmaceutics14061224. Pharmaceutics. 2022. PMID: 35745797 Free PMC article.
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.
Bellesoeur A, Gataa I, Jouinot A, Mershati SE, Piketty AC, Tlemsani C, Balakirouchenane D, Monribot A, Vidal M, Batista R, de Percin S, Villeminey C, Alexandre J, Goldwasser F, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A. Bellesoeur A, et al. Among authors: thomas schoemann a. Cancer Chemother Pharmacol. 2021 Oct;88(4):741-751. doi: 10.1007/s00280-021-04311-4. Epub 2021 Jul 24. Cancer Chemother Pharmacol. 2021. PMID: 34304283
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C. Slimano F, et al. Among authors: thomas schoemann a. Cancer Treat Rev. 2020 Aug;88:102063. doi: 10.1016/j.ctrv.2020.102063. Epub 2020 Jun 23. Cancer Treat Rev. 2020. PMID: 32623296 Free PMC article. Review.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: thomas schoemann a. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
The impact of body composition parameters on severe toxicity of nivolumab.
Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F. Hirsch L, et al. Among authors: thomas schoemann a. Eur J Cancer. 2020 Jan;124:170-177. doi: 10.1016/j.ejca.2019.11.003. Epub 2019 Nov 30. Eur J Cancer. 2020. PMID: 31794927
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B. Bellesoeur A, et al. Among authors: thomas schoemann a. Cancers (Basel). 2019 Nov 13;11(11):1784. doi: 10.3390/cancers11111784. Cancers (Basel). 2019. PMID: 31766292 Free PMC article.
Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML, Carton E, Jouinot A, Allard M, Huillard O, Khoudour N, Peyromaure M, Zerbib M, Schoemann AT, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Joulia ML, et al. Among authors: schoemann at. Clin Genitourin Cancer. 2020 Apr;18(2):155-160. doi: 10.1016/j.clgc.2019.05.020. Epub 2019 Jun 13. Clin Genitourin Cancer. 2020. PMID: 31630979
44 results